Wilmington, DE, October 06, 2011 --(PR.com
)-- These expansions come following the company’s recent productive results from successful preclinical studies for three novel candidates in the treatment of chronic pain and inflammatory conditions.
FyMed has developed a portfolio of novel drugs by opportunistically leveraging drug discovery with innovative and proprietary technologies in pharmacogenomics and proteomics. This has enabled the company to overcome market size limitations of current personalized medicine based approaches, which primarily are due to inherent differences in the heterogeneity of treatment effects. FyMed has utilized these methodologies to identify and validate expansive reproducible clusters of novel biomarker-based therapeutic response patterns within patient populations. This led the company to develop combinatory approaches that have enabled major breakthroughs in the discovery and development of several innovative pharmaceutical formulations. The company has successfully completed preclinical studies with three promising candidates from these formulations, and obtained striking results with profound therapeutic clinical response that demonstrated the value and potential of significant impact in major disease markets.
The projected reinforcements will now enable FyMed to conduct clinical trials with innovative drug-centric model approaches. These expansions will integrate clinical study indices and results with phenotypic molecular, pharmacological, genomic, and proteomic data, and additionally enable more safer and effective drugs that will be in favor of both patient compliance and product approval.
FyMed, Inc. is a biopharmaceutical company with a growing portfolio of novel and improved pharmaceuticals that were developed and enhanced through next generation ultra-sensitive targeted companion diagnostics and prognostics. Leading innovations in personalized medicine has enabled FyMed to effectively balance technological innovation with scientific discovery, creating tools that can productively integrate with drug development and capitalize on key market deficiencies. Additional information is available through FyMed Media Relations or at www.fymed.com.
Safe Harbor Statement
To the extent any statements made in this document contain information that is not historical, this news release contains "forward-looking statements" within the meaning of Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of the words "intends," "plans," "will," "potential," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described herein. These risks and uncertainties may include, without limitation, projected expansions, outcomes of our clinical trials, achievement of our business objectives, and the ability to obtain necessary regulatory approvals. FyMed undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise.